Published in Arch Virol on January 01, 1988
Neuronal cell surface molecules mediate specific binding to rabies virus glycoprotein expressed by a recombinant baculovirus on the surfaces of lepidopteran cells. J Virol (1998) 1.14
The pathogenetic basis of viral tropism. Am J Pathol (1989) 0.95
Development and evaluation of an in vitro virus isolation procedure as a replacement for the mouse inoculation test in rabies diagnosis. J Clin Microbiol (1989) 0.95
Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: an in vitro and in vivo study. J Gen Virol (2000) 2.29
Tetanus toxin. Microbiol Rev (1979) 2.25
Adjuvants--a balance between toxicity and adjuvanticity. Vaccine (1993) 1.86
Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J Gen Virol (1987) 1.73
Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci U S A (1998) 1.68
Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol (1999) 1.65
Metal regulation of siderophore synthesis in Pseudomonas aeruginosa and functional effects of siderophore-metal complexes. Appl Environ Microbiol (1992) 1.58
Cloning and nucleotide sequence of the pvdA gene encoding the pyoverdin biosynthetic enzyme L-ornithine N5-oxygenase in Pseudomonas aeruginosa. J Bacteriol (1994) 1.58
C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci U S A (1998) 1.57
Iron-regulated salicylate synthesis by Pseudomonas spp. J Gen Microbiol (1993) 1.45
Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun (1984) 1.45
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci U S A (2000) 1.42
Iron-regulated transcription of the pvdA gene in Pseudomonas aeruginosa: effect of Fur and PvdS on promoter activity. J Bacteriol (1996) 1.41
Functional analysis of PvdS, an iron starvation sigma factor of Pseudomonas aeruginosa. J Bacteriol (2000) 1.40
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol (1999) 1.38
Entry pathway of vesicular stomatitis virus into different host cells. J Gen Virol (1987) 1.31
Evidence for an intraaxonal transport of fixed and street rabies virus. J Neuropathol Exp Neurol (1979) 1.26
An antigenic polypeptide fragment isolated from tetanus toxin: chemical characterization, binding to gangliosides and retrograde axonal transport in various neuron systems. J Neurochem (1977) 1.26
Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.20
Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC). Biomed Pharmacother (1998) 1.16
Isolation and characterization of Pseudomonas aeruginosa mutants blocked in the synthesis of pyoverdin. J Bacteriol (1992) 1.11
Rabies virus infection of cultured rat sensory neurons. J Virol (1987) 1.10
Electrostatic interactions in the early events of VSV infection. Res Virol (1991) 1.07
Papain-derived fragment IIc of tetanus toxin: its binding to isolated synaptic membranes and retrograde axonal transport. Brain Res (1981) 1.07
Transplacental transmission of human polyomavirus BK. J Med Virol (1998) 1.06
Chemical characterization of tetanus toxin and toxoid. Amino acid composition, number of SH and S-S groups and N-terminal amino acid. Eur J Biochem (1970) 1.04
Experimental modification of postnatal cerebellar granule cell migration in vitro. Brain Res (1986) 1.04
Capacity of staphylococci to grow in the presence of ovotransferrin or CrCl3 as a character of potential pathogenicity. J Clin Microbiol (1980) 1.03
Electrophysiological and sleep alterations in experimental mouse rabies. Brain Res (1986) 1.03
[The preparation of rabies virus nucleocapsid specific IgG and its purification and conjugation with peroxidase or fluorescein isothiocyanate (author's transl)]. Ann Microbiol (Paris) (1976) 1.02
Involvement of gangliosides in rabies virus infection. J Gen Virol (1986) 1.01
Rearrangement patterns of JC virus noncoding control region from different biological samples. J Neurovirol (2003) 1.01
[Production and purification of tetanus toxin]. Ann Inst Pasteur (Paris) (1969) 1.00
Mechanism of rabies virus entry into CER cells. J Gen Virol (1984) 0.99
Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch Pharmacol (1981) 0.99
Receptors for BK virus on human erythrocytes. Acta Virol (1981) 0.98
Delayed-type hypersensitivity to rabies virus in mice: assay of active or passive sensitization by the footpad test. Infect Immun (1978) 0.98
Rabies virus selectively alters 5-HT1 receptor subtypes in rat brain. Eur J Pharmacol (1993) 0.98
[Extraction of a soluble antigen (a glycoprotein) from rabies tissue culture vaccines using Triton X100. Immunization and protection experiments (author's transl)]. Ann Microbiol (Paris) (1974) 0.98
Detection of JC and BK viral genome in specimens of HIV-1 infected subjects. New Microbiol (1997) 0.98
Involvement of gangliosides in the interaction between BK virus and Vero cells. Arch Virol (1990) 0.96
Inhibition of BK virus haemagglutination by gangliosides. J Gen Virol (1987) 0.96
Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine (1998) 0.95
Rapid diagnosis of rabies infection by means of a dot hybridization assay. Mol Cell Probes (1988) 0.95
Axonal transport of rabies virus in the central nervous system of the rat. J Neuropathol Exp Neurol (1986) 0.95
Monoclonal antibodies against tetanus toxin and toxoid. Med Microbiol Immunol (1983) 0.95
Effect of isoflavans and isoflavenes on the infection of Frp/3 cells by hepatitis A virus. Antiviral Res (1989) 0.95
Pathway of rubella virus infectious entry into Vero cells. J Gen Virol (1996) 0.94
Naturally acquired antibodies to tetanus toxin in humans and animals from the galápagos islands. J Infect Dis (1983) 0.94
Polymerase chain reaction amplification of rabies virus nucleic acids from total mouse brain RNA. Mol Cell Probes (1990) 0.94
Use of the B-IIb tetanus toxin derived fragment as a specific neuropharmacological transport agent. Brain Res (1980) 0.94
Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev (2003) 0.94
Alteration of the actin-based cytoskeleton by rabies virus. J Gen Virol (1997) 0.94
[Immunological and biological study of subunits of tetanus toxin]. C R Acad Sci Hebd Seances Acad Sci D (1974) 0.93
Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis (2007) 0.92
On the structure of tetanus toxin. Naunyn Schmiedebergs Arch Pharmacol (1973) 0.92
Effect of isoflavans and isoflavenes on rhinovirus 1B and its replication in HeLa cells. Antiviral Res (1988) 0.92
Effect of polyions on the early events of Sindbis virus infection of Vero cells. Arch Virol (1991) 0.92
Role of phospholipids in rhabdovirus attachment to CER cells. Brief report. Arch Virol (1984) 0.91
An in vivo and in vitro study of rabies virus infection of the rat superior cervical ganglia. Arch Virol (1983) 0.91
[Purification and properties of streptococcal erythrogenic toxin]. Ann Inst Pasteur (Paris) (1968) 0.91
Involvement of alpha-interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment. Biomed Pharmacother (1994) 0.91
[In vivo inhibition of rabies virus multiplication by an endogenous interferon]. Ann Inst Pasteur (Paris) (1970) 0.90
Inhibition of herpes simplex virus infection by negatively charged and neutral carbohydrate polymers. J Chemother (1995) 0.90
[Antirabies vaccines from tissue culture obtained with the Pasteur strain. Results of vaccination]. Ann Inst Pasteur (Paris) (1972) 0.90
In vivo detection of specific cell-mediated immunity in street rabies virus infection in mice. J Gen Virol (1980) 0.90
Growth of Legionella spp. under conditions of iron restriction. J Med Microbiol (1991) 0.90
Enhanced antimicrobial activity of lactoferrin by binding to the bacterial surface. Microbiologica (1988) 0.90
Molecular combing. Curr Protoc Cytom (2001) 0.90
Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.89
Sleep alterations in experimental street rabies virus infection occur in the absence of major EEG abnormalities. Brain Res (1991) 0.89
Activities and mechanisms of action of halogen-substituted flavanoids against poliovirus type 2 infection in vitro. Antimicrob Agents Chemother (1990) 0.89
Tat toxoid as a component of a preventive vaccine in seronegative subjects. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.89
Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy. Biomed Pharmacother (1999) 0.88
Monoclonal antibody A2B5, which detects cell surface antigens, binds to ganglioside GT3 (II3 (NeuAc)3LacCer) and to its 9-O-acetylated derivative. J Biol Chem (1990) 0.88
Neurotropism of rabies virus. An in vitro study. J Neuropathol Exp Neurol (1983) 0.88
Preparation of conjugates using two tetanus toxin derived fragments: their binding to gangliosides and isolated synaptic membranes and their immunological properties. Toxicon (1980) 0.87
Modification of tritiated gamma-amino-n-butyric acid transport in rabies virus-infected primary cortical cultures. J Gen Virol (1994) 0.87
Inhibition of rabies virus in vitro by the ammonium-5-tungsto-2-antimoniate. J Gen Virol (1978) 0.87
Role of membrane phospholipids and glycolipids in the Vero cell surface receptor for rubella virus. Med Microbiol Immunol (1990) 0.87
Neuronal function impairment in rabies-infected rat brain. J Gen Virol (1982) 0.87
[Mechanism of detoxification by formol]. C R Acad Sci Hebd Seances Acad Sci D (1965) 0.87
Siderophore production by Salmonella species isolated from different sources. FEMS Microbiol Lett (1991) 0.87
Inhibition of rabies virus transcription in rat cortical neurons with the dissociative anesthetic ketamine. Antimicrob Agents Chemother (1992) 0.87
Virulence determinants in Pseudomonas aeruginosa strains from urinary tract infections. Epidemiol Infect (1992) 0.87
Induction of immunoreactive interleukin-1 beta and tumor necrosis factor-alpha in the brains of rabies virus infected rats. J Neuroimmunol (1996) 0.87
One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy. J Acquir Immune Defic Syndr (1992) 0.87
Antiviral activity of natural and semisynthetic polysaccharides on the early steps of rubella virus infection. J Antimicrob Chemother (1997) 0.87
Interaction of Clostridium perfringens delta toxin with erythrocyte and liposome membranes and relation with the specific binding to the ganglioside GM2. Toxicon (1989) 0.86
Immunochemistry of tetanus toxin. The nitration of tyrosyl residues in tetanus toxin. Eur J Biochem (1973) 0.86
Study of receptors for vesicular stomatitis virus in vertebrate and invertebrate cells. Microbiologica (1986) 0.86
Susceptibility of mammalian, avian, fish, and mosquito cell lines to rabies virus infection. Acta Virol (1990) 0.86
[Degradation of the beta-hydroxybutyric lipid by an enzyme extract of Bacillus megatherium I, depolymease A]. C R Acad Sci Hebd Seances Acad Sci D (1966) 0.86
[Rabies anti-glycoprotein IgG conjugated with peroxidase and fluorescein isothiocyanate (author's transl)]. Ann Microbiol (Paris) (1976) 0.85